- Home
- RC vs GYRE Comparison
RC vs GYRE Comparison
Compare RC & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RC
- GYRE
- Stock Information
- Founded
- RC 2007
- GYRE 2002
- Country
- RC United States
- GYRE United States
- Employees
- RC N/A
- GYRE N/A
- Industry
- RC Real Estate Investment Trusts
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- RC Real Estate
- GYRE Health Care
- Exchange
- RC Nasdaq
- GYRE Nasdaq
- Market Cap
- RC 1.2B
- GYRE 1.3B
- IPO Year
- RC N/A
- GYRE N/A
- Fundamental
- Price
- RC $7.26
- GYRE $11.14
- Analyst Decision
- RC Hold
- GYRE
- Analyst Count
- RC 10
- GYRE 0
- Target Price
- RC $29.25
- GYRE N/A
- AVG Volume (30 Days)
- RC 2.0M
- GYRE 144.6K
- Earning Date
- RC 11-07-2024
- GYRE 11-13-2024
- Dividend Yield
- RC 13.77%
- GYRE N/A
- EPS Growth
- RC N/A
- GYRE N/A
- EPS
- RC N/A
- GYRE N/A
- Revenue
- RC $140,359,000.00
- GYRE $105,033,000.00
- Revenue This Year
- RC N/A
- GYRE $25.32
- Revenue Next Year
- RC $13.62
- GYRE $12.95
- P/E Ratio
- RC N/A
- GYRE N/A
- Revenue Growth
- RC N/A
- GYRE N/A
- 52 Week Low
- RC $6.65
- GYRE $8.26
- 52 Week High
- RC $11.11
- GYRE $30.39
- Technical
- Relative Strength Index (RSI)
- RC 48.69
- GYRE 47.54
- Support Level
- RC $7.17
- GYRE $9.61
- Resistance Level
- RC $7.64
- GYRE $12.94
- Average True Range (ATR)
- RC 0.22
- GYRE 1.17
- MACD
- RC -0.03
- GYRE 0.13
- Stochastic Oscillator
- RC 40.63
- GYRE 47.06
About RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.